Construção e validação de curso on-line sobre a administração do anticorpo monoclonal palivizumabe

Abstract

The Palivizumab is a monoclonal antibody indicated for the prevention of severe lower respiratory tract disease caused by respiratory syncytial virus, and the nurse is the professional responsible for the preparation and administration. Thus, it is important to create educational technologies for training these professionals. The aim of this study was to construct and validate educational technology, such as the online course, on the administration of monoclonal antibody Palivizumab to nurses. Methodological study, developed from April/2017 to August/2018. For construction, the Digital Educational Material Development Model developed by Falkembach (2005) was used, composed of the phases of analysis and planning, modeling and implementation. Next, in the evaluation and maintenance phase, content and appearance validation was performed by specialists. The distribution phase will be done in a later study. Study approved by the Research Ethics Committee of the Federal University of Ceará, according to protocol nº 2.004.299. The course was created in HTML pages and divided into three classes that covered the following topics: Acute respiratory infections; Knowing the respiratory syncytial virus; Signs, symptoms, treatment and prevention of respiratory syncytial virus; Knowing Palivizumab; Administration of Palivizumab; Care in the administration of Palivizumab in children; Networks credentials of application of Palivizumab; and Importance of the family in the process of administration of Palivizumab. Validation was carried out with 11 judges specialized in the neonatal and pediatric area and four judges in the area of computing, computer science, EaD, Web designer. Data evaluated according to the Content Validity Index (CVI) and organized in Excel. In the validation of content, the items had agreement above 0.80, with a total CVI of 1.0, demonstrating that the content of the course is valid, being this adequate and updated for nurses. Regarding the validation of appearance, 63.6% of the items were considered adequate by the judges, presenting individual CVI of 0.5 and 1.0 and total CVI of 0.63. Before the comments and suggestions, from the validation, the most debated were: scarce information about the author and the advisor; images visibly in excess; improvement of image quality and graphic design; non-uniformity in the presentation of text boxes; some outdated references; highlight the selection criteria for receiving Palivizumab; resizing of images and videos. Therewith, the online course was changed and set to the judges in appearance for re-evaluation. The second evaluation resulted in the individual and total CVI of 1.0, being considered as excellent among judges, concluding a valid online course for nurses. Therefore, the second evaluation of the judges in appearance became relevant to evaluate if the suggestions provided by them, in the first evaluation, were followed for improvement of the course and, thus, adequacy to the result of the CVI, becoming fundamental for the improvement of educational technology, thus resulting in a quality online course. It is concluded that the online course "Monoclonal Antibody Palivizumab: Nursing and Prophylaxis for the Syncytial Virus" was validated and considered as innovative technology for nurses in the monoclonal antibody Palivizumabe. It can also be considered that the course can be applied as a technology focused on health education in the area of teaching and care, training not only nurses, but also other health professionals, thus collaborating to improve related public policies to this monoclonal antibody in Ceará and Brazil.